The European medicines regulator said on Monday it would hold a meeting this week on the information gathered into whether the AstraZeneca COVID-19 vaccine contributed to thromboembolic events in those inoculated.

While its investigation is ongoing, the European Medicines Agency remains of the view that the benefits of the AstraZeneca vaccine in preventing COVID-19 outweigh the risks of side effects. 

(c) Reuters



Similar articles:

  1. Croatian Agency for Medicinal Products and Devices Inspecting Documentation on Russian Vaccine []
  2. European firms agree to produce Russia’s COVID-19 jab []
  3. WHO adds Janssen vaccine to list of safe and effective emergency tools against COVID−19 []

Leave a Reply

Your email address will not be published. Required fields are marked *